TRVI Stock Forecast & Price Target

Trevi Therapeutics is well-positioned to draft off of strong economic conditions, creating potential upside for the stock. Recent commentary shows solid and improving credit performance across businesses and consumers. Trevi has a unique and differentiated clinical profile for their investigational therapy Haduvio, with demonstrated efficacy in multiple chronic cough populations and development underway for multiple indications with potential multi-billion dollar peak sales opportunities.GSK's decision to halt development of their P2X3 antagonist in RCC validates Haduvio's potential as the leading candidate in this indication. Even with the loss of GSK's market-building investment, Trevi has a credible standalone path to success and is well-positioned for potential strategic discussions. Their data shows a broad range of efficacy for Haduvio and a potential for addressing a large market opportunity. However, there are still regulatory and financing risks that investors should be aware of.

Trevi Therapeutics is a clinical-stage biopharmaceutical company that has recently received significant attention due to their investigational therapy, Haduvio. However, despite the potential in the later-line market it was initially targeting, the company now faces significant risk due to GSK's exit and the need to expand into the broader RCC population. Moreover, while Trevi's analysis indicates favorable efficacy and tolerability at lower doses, the decreases in cough frequency were dose-dependent in non-antifibrotic users, but not in high-dose antifibrotic users, raising concerns about potential PK interactions.